PARKE DAVIS
Big PharmaPARKE DAVIS is a major pharmaceutical company focused on Neurology, Infectious Disease, Dermatology.
PARKE DAVIS's Key Drugs
PARKE DAVIS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PARKE DAVIS's Recent FDA Approvals
New NDA/BLA approvals for PARKE DAVIS over the last two years — novel drugs only, excluding generics and label supplements.
PARKE DAVIS's Therapeutic Areas
PARKE DAVIS's approved drugs and pipeline span 3 therapeutic areas, led by Neurology and Infectious Disease, across 0 biologic and 7 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PARKE DAVIS's Top Competitors
PARKE DAVIS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PAI HOLDINGS, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PARKE DAVIS Pipeline Snapshot
Active clinical trials for PARKE DAVIS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1953-09-08
- Latest
- 2022-04-28
- Applications
- 105